GLORIA

GEOMAR Library Ocean Research Information Access

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • American Association for Cancer Research (AACR)  (44)
  • 1
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 73, No. 8_Supplement ( 2013-04-15), p. 4602-4602
    Abstract: Recent genetic studies have revealed a number of novel gene mutations in myeloid malignancies, unmasking an unexpected role of deregulated histone modification and DNA methylation in myeloid neoplasms. However, our knowledge about the spectrum of gene mutations in myeloid neoplasms is still incomplete. So, we analyzed 50 paired tumor-normal samples of myeloid neoplasms using whole exome sequencing, among which we identified recurrent mutations involving STAG2, a core cohesin component, and two other cohesin components, including STAG1 and PDS5B. Cohesin is a multimeric protein complex which is composed of four core subunits (SMC1, SMC3, RAD21 and STAG proteins), and is engaged in cohesion of sister chromatids, DNA repair and transcriptional regulation. To extend the findings in the whole-exome analysis, an additional 534 primary samples of various myeloid neoplasms was examined for mutations and deletions in a total of 9 components of the cohesin complexes, using high-throughput sequencing and SNP arrays. In total, mutations/deletions were found in a variety of myeloid neoplasms, including AML (22/131), CMML (15/86), MDS (26/205), in a mutually exclusive manner. Cohesin mutations frequently coexisted with other common mutations in myeloid neoplasms, significantly associated with spliceosome mutations. Deep sequencing of these mutant alleles revealed that majority of the cohesin mutations existed in the major tumor populations, indicating their early origin during leukemogenesis. Next, we examined several myeloid leukemia cell lines with or without cohesin mutations for expression of each cohesin component and their chromatin-bound fractions. Interestingly, the chromatin-bound fraction of several components of cohesin was significantly reduced in cell lines having mutated or defective cohesin components, suggesting substantial loss of cohesin-bound sites on chromatin. Finally, we introduced the wild-type RAD21 allele into RAD21-mutated cell lines (Kasumi-1), which effectively suppressed the proliferation of Kasumi-1, supporting a leukemogenic role of compromised cohesin functions. Less frequent mutations of cohesin components have been described in other cancers, where impaired cohesion and consequent aneuploidy were implicated in oncogenic action. However, about half of cohesin-mutated cases in our cohort had completely normal karyotypes, suggesting that cohesin-mutated cells were not clonally selected because of aneuploidy. Of note, the number of mutations determined by our whole exome analysis was significantly higher in cohesin-mutated cases compared to non-mutated cases. Since cohesin participates in post-replicative DNA repair, this may suggest that compromised cohesin function could induce DNA hypermutability and contribute to leukemogenesis. In conclusion, our findings highlight a possible role of compromised cohesin functions in myeloid leukemogenesis. Citation Format: Ayana Kon, Lee-Yung Shih, Masashi Minamino, Masashi Sanada, Yuichi Shiraishi, Yasunobu Nagata, Kenichi Yoshida, Yusuke Okuno, Masashige Bando, Shunpei Ishikawa, Aiko Sato-Otsubo, Genta Nagae, Aiko Nishimoto, Claudia Haferlach, Daniel Nowak, Yusuke Sato, Tamara Alpermann, Teppei Shimamura, Hiroko Tanaka, Kenichi Chiba, Ryo Yamamoto, Tomoyuki Yamaguchi, Makoto Otsu, Naoshi Obara, Mamiko Sakata-Yanagimoto, Tsuyoshi Nakamaki, Ken Ishiyama, Florian Nolte, Wolf-Karsten Hofmann, Shuichi Miyawaki, Shigeru Chiba, Hiraku Mori, Hiromitsu Nakauchi, H. Phillip Koeffler, Hiroyuki Aburatani, Torsten Haferlach, Katsuhiko Shirahige, Satoru Miyano, Seishi Ogawa. Recurrent pathway mutations of multiple components of cohesin complex in myeloid neoplasms. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 4602. doi:10.1158/1538-7445.AM2013-4602
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2013
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 2
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 74, No. 19_Supplement ( 2014-10-01), p. 2223-2223
    Abstract: Introduction and Objective Testicular germ cell cancer (TGCC) is the most common solid malignancy among young adult males. Cure could be obtained by intensive chemotherapy combined with retroperitoneal lymph node dissection, but often with substantially compromised quality of life. As for the common genetic lesions, somatic mutations and amplifications of KIT are found in about 20%-30% of cases with TGCCs. However, the molecular pathogenesis of TGCC is still poorly understood. In this study, to obtain a better understanding of the genetic basis of TGCC and to identify druggable molecular targets, we performed whole exome sequencing as well as SNP array-based copy number analysis in TGCC. Methods All cases underwent high orchiectomy and were histologically diagnosed as TGCC. Genomic DNA was extracted from fresh frozen specimens of TGCC. Whole exome sequencing was performed for paired tumor/normal DNA from 10 TGCC patients, in which target exomes were captured using SureSelect Human All Exon V5 (Agilent Technologies) and subjected to massively parallel sequencing on the Illumina platform (HiSeq2000). Copy number variants were also interrogated in 40 TGCCs (25 seminomas and 15 non-seminomas) using Affymetrix 250K NspI array. Results TGCC genome was triploid in most cases with high level amplification in12p. Loss of heterozygosity (LOH) of chromosome 4 was frequently observed in both seminoma and non-seminoma, whereas 11q deletion was found predominantly in cases with seminoma. In addition, we identified recurrent focal amplifications involving 4q12 and 22q11, from which KIT and MAPK1 were identified, respectively. In whole exome sequencing, 15 somatic mutations were detected per sample on average, which was relatively lower than other solid malignancies. When combined the results of copy number analysis with those of whole-exome sequencing, genes involved in RAS signaling pathway and chromatin modification were frequently altered in TGCC. Conclusions Our comprehensive analyses revealed genomic aberrations of TGCC in terms of copy number alterations and gene mutations. Mutated/amplified KIT and MAPK1 and other RAS pathway gene could be potential targets of small molecule inhibitors for therapeutics. Citation Format: Yusuke Sato, Aiko Sato-Otsubo, Yasunobu Nagata, Kenichi Yoshida, Yuichi Shiraishi, Hiromichi Suzuki, Masashi Sanada, Haruki Kume, Satoru Miyano, Yukio Homma, Seishi Ogawa. Genome-wide analysis of copy number alterations and gene mutations in testicular germ cell cancer. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 2223. doi:10.1158/1538-7445.AM2014-2223
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2014
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 3
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 72, No. 8_Supplement ( 2012-04-15), p. 5119-5119
    Abstract: MDS are a group of myeloid neoplasms characterized by deregulated blood cell production and a high propensity to AML. Although a number of gene alterations have been implicated in the pathogenesis of MDS, they do not fully explain the pathogenesis of MDS. So, in order to clarify a comprehensive registry of gene mutations in MDS, we performed whole-exome sequencing of 29 cases with MDS and related myeloid neoplasm. A total of 268 somatic mutations or 9.2 mutations per sample were identified. Among these 9 genes were mutated in more than 2 cases, which not only included a spectrum of known gene targets in MDS, but also affected previously unknown genes that are commonly involved in RNA splicing pathway, including U2AF35, SRSF2 and ZRSR2. Together with additional three (SF3A1, SF3B1 and PRPF40B) found in single cases, 16 (55.2%) of the 29 discovery cases carried a mutation affecting the component of the splicing machinery. To confirm the observation, we examined 9 spliceosome genes for mutations in a large set of myeloid neoplasms. In total, 219 mutations were identified in 209 out of the 582 samples of myeloid neoplasms. RNA splicing pathway mutations were highly specific to myelodysplasia, including 19 of 23 (83%) cases with RARS, 43 of 50 (86%) RCMD-RS, 68 of 155 (44%) other MDS, 48 of 88 (55%) CMML, and 16 of 62 (26%) secondary AML with MDS features with a string preference of SF3B1 mutations to RARS and RCMD-RS and of SRSF2 to CMML, while they were rare in cases with de novo AML and MPN. Significantly, these mutations occurred in an almost completely mutually exclusive manner among mutated cases, suggesting the importance of deregulated RNA splicing in the pathogenesis of MDS. RNA splicing plays critical roles in differentiation, development, and disease and is a major source for protein diversity in higher eukaryotes. Splicing pathway mutations in myelodysplasia commonly affected those components of the splicing complex that are engaged in the 3′ splice site recognition, strongly indicating production of unspliced or aberrantly spliced RNA species are incriminated for the pathogenesis of MDS. So, to clarify the effect of these splicing mutations on RNA splicing, we expressed the wild-type and the mutant U2AF35 or SRSF2 in HeLa cells and performed whole transcriptome analysis in these cells. The results of exon array showed that the wild-type U2AF35 promoted RNA splicing correctly, whereas the mutant U2AF35 inhibited this processes and rendered intronic sequences to remain unspliced. RNA sequencing additionally showed that the number of reads that encompassed the exon/intron junctions was significantly increased in mutant U2AF35-transduced cells. This result means that mutant U2AF35 actually induced impaired 3′-splice site recognition during pre-mRNA processing. In conclusion, our study demonstrated that abnormal RNA splicing caused by mutations of multiple genes on RNA splicing pathway is a common feature of myelodysplasia. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 5119. doi:1538-7445.AM2012-5119
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2012
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 4
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 72, No. 8_Supplement ( 2012-04-15), p. 5122-5122
    Abstract: Myelodysplastic syndromes (MDS) are a heterogeneous group of chronic myeloid neoplasms showing a predisposition to acute myeloid leukemia (AML). The recent discovery of novel pathway mutations of the RNA splicing machinery provided a new insight into the pathogenesis of MDS. These splicing pathway mutations are highly prevalent among all MDS subtypes, accounting for 45 to 85% of the cases. However, the frequency of mutations shows substantial variations among disease subtypes, the genetic/biological basis of which has not been clarified. In addition, the impact of splicing pathway mutations on prognosis has been poorly defined. To explore the genetic basis for these differences, we analyzed genome-wide copy number lesions and the spectrum of gene mutations that may coexist with splicing pathway mutations in a set of 283 cases with myelodysplasia, using SNP array karyotyping and target sequencing of common gene targets in MDS, including TET2 and EZH2. The effects of the splicing pathway mutations on clinical outcomes were evaluated together with those of these accompanying genetic lesions. Splicing pathway mutations were identified in 160 (57%) among 8 components of the splicing machinery, which occurred in a mutually exclusive manner. SNP array karyotyping revealed 138 cases (49%) showing copy number alterations, in which 7q- and/or 5q- were the most frequent abnormalities. Interestingly, the splicing pathway mutations were found at a significantly lower frequency among patients with 7q- and/or 5q- (p & lt;0.0001), where multivariate analysis revealed that 7q- and/or 5q- were independently and significantly associated with the lower frequency of spliceosome mutation (p = 0.001 for 7q- and p = 0.029). 7q- and/or 5q- with complex karyotypes were associated with a significantly poor prognosis (p = 0.025, log-rank test), the presence of the splicing pathway mutations had no impact on prognosis. Interestingly, however, the presence of 7q- and/or 5q- do not seem to be a risk of poor prognosis among those patients carrying a splicing pathway mutation, suggesting that the presence of a splicing pathway mutation could have a beneficial effect on the prognosis of patients with 7q- and/or 5q-. In total, 172mutations were identified among 117 samples, including 41 TET2 (25%), 32 RUNX1 (20%), 26 ASXL1 (16%), 24 RAS (15%), 22 TP53 (14%), 17 IDH1/2 (10%), 10 CBL (6%) and 10 EZH2 (6%) mutations. No specific association between splicing pathway mutations and other coexisting mutations, except that the SRSF2 mutations were significantly associated with lower numbers of accompanying gene mutations compared with that of the U2AF35 mutations (N=14) (OR 6.2 95%CI 1.1-35), which may be of potential interest in the light of the previous report that SRSF2 was involved in the regulation of DNA stability and that depletion of SRSF2 can induce genomic stability. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 5122. doi:1538-7445.AM2012-5122
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2012
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 5
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 72, No. 8_Supplement ( 2012-04-15), p. 2092-2092
    Abstract: Renal cell carcinoma (RCC) is the most common form of adult kidney cancer and accounts for 2-3% of all adult malignancies, in which clear cell carcinoma accounts for more than 80% of the cases. As for the pathogenesis of clear cell RCC, inactivation of the VHL gene has been reported in 80% of clear cell RCC and more recently, frequent mutations of epigenetic regulators, including PBRM1, SETD2, KDM5C and UTX, have been demonstrated through high-throughput mutation studies, including PBRM1 has been demonstrated in ∼40% of the cases. Nevertheless, probably, our knowledge of the full spectrum of gene mutations in RCC is still incomplete. In this study, to obtain a better understanding of molecular pathogenesis of clear cell RCC, we performed an integrated genetic study of clear cell RCC, where a total of 93 paired specimens were analyzed by massively parallel sequencing of SureSelect (Agilent)-enriched whole exomes, SNP array-based copy number analysis (Affymetrix), as well as gene expression profiling (Agilent). In whole exome sequencing, 42 somatic mutations per sample were identified on average, which involved not only previously reported genes, but also a number of novel gene targets. Among these, mutations of genes involved in chromatin regulation or histone modification were preferentially found in advanced cases. To understand whole picture of gene mutations of epigenetic mechanism in clear cell RCC, mutation analysis of 85 genes involved in chromatin regulation or histone modification were performed in 180 cases using multiplexed barcode sequencing. A total of 201 somatic mutations were validated and 74% cases had at least one somatic mutation. PBRM1 mutations were found in 43% cases and SETD2 were mutated in 10% of cases. When comparing clinical picture with mutation status, SETD2 mutation was associated with the risk of metastasis, while PBRM1 mutations had no impact on prognosis. Our results showed that in clear cell RCC, multiple component of complexes involved in epigenetic regulation undergo gene mutations, confirming that deregulated epigenetic apparatus play important roles in pathogenesis of clear cell RCC. In this meeting, we will present the result of our integrated genetic analysis of RCC and discuss the genetic basis of RCC in terms of copy number alterations, gene mutations, as well as gene expression profiles. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 2092. doi:1538-7445.AM2012-2092
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2012
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 6
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 73, No. 8_Supplement ( 2013-04-15), p. 3184-3184
    Abstract: Clear cell renal cell carcinoma (ccRCC) is the most common form of adult kidney cancer. The most frequent genetic event in the evolution of ccRCC is inactivation of the von Hippel-Lindau (VHL) tumor suppressor gene. Recent studies have revealed frequent mutations of PBRM1 as well as other epigenetic regulators including BAP1, SETD2 and KDM5C, but their impact on therapeutics remains unclear. In this study, to obtain a better understanding of molecular pathogenesis of ccRCC, we performed an integrated genetic study of ccRCC including whole exome sequencing, copy number analysis as well as transcriptome and methylome analysis. A total of 106 paired specimens were analyzed by massively parallel sequencing of whole exomes (Agilent SureSelect, Illumina HiSeq2000) and SNP array-based copy number analysis (Affymetrix 250K array) as well as gene expression (Agilent Human Gene Expression 4x44k v2) and methylation (Illumina Infinium 450K) profiling and RNA sequencing (Illumina HiSeq2000). On average, 48.8 somatic mutations per sample were identified in whole exome analysis, in which VHL mutations were most frequent. PBRM1, BAP1 and SETD2 were also recurrently mutated and were further analyzed in 240 cases together with an additional 80 genes involved in chromatin regulation. PBRM1 mutations were found in 42% of the cases, while BAP1 and SETD2 were mutated in 12% and 10%, respectively. BAP1 mutations correlated with poor prognosis and SETD2 mutation was associated with the risk for metastatic diseases. Pathway analysis revealed frequent mutations of genes involved in mRNA processing. Among them, mutations of genes involved in 3’ splice site recognition, which were frequently mutated in MDS, were rare. Most of them were involved in release of intron, 3’-end processing or export to cytoplasm. In expression analysis, tumors were clustered into two clusters known as ccA and ccB, in which the ccA type was characterized by overexpressed genes involved in angiogenesis, whereas expression of genes in cell cycle regulators were a prominent feature in the ccB type tumors. In methylome analysis, 15 samples were clustered into hypermethylated subtype where all cases were included in the ccB type and were associated with poor prognosis. Homeobox genes were differently methylated in hypermethylated subtype which indicate deregulation of polycomb mediated gene silencing induce high-grade ccRCC. RUNX1 and SRPX2 were differently methylated between ccA type and ccB type, which may affect the differences of expression profile between two subtypes. In RNA sequencing, known fusion gene involving TFE3 and NONO was detected in single case. In total, 34 fusion genes were detected in 23 samples, although no recurrent fusion genes have been identified. Our results indicate that genomic analyses are useful for classification, prognostic prediction and development of treatment strategy in ccRCC. Citation Format: Yusuke Sato, Shigekatsu Maekawa, Yusuke Okuno, Yuichi Shiraishi, Aiko Sato, Genta Nagae, Teppei Shimamura, Yasunobu Nagata, Kenichi Yoshida, Masashi Sanada, Haruki Kume, Hiroyuki Aburatani, Satoru Miyano, Yukio Homma, Seishi Ogawa. Integrative analysis of clear cell renal cell carcinoma. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 3184. doi:10.1158/1538-7445.AM2013-3184
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2013
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 7
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 72, No. 8_Supplement ( 2012-04-15), p. 5117-5117
    Abstract: Myelodysplastic syndromes and related myeloid neoplasms (myelodysplasia) are a heterogeneous group of clonal disorders showing deregulated blood cell production and a predisposition to acute myeloid leukemia, whose pathogenesis is only incompletely understood. So, to clarify the molecular pathogenesis of myelodysplasia, we performed whole-exome sequencing of paired tumor/control DNA from 29 patients with myelodysplasia, leading to the identification of novel pathway mutations of the splicing machinery in myelodysplasia (Yoshida et al., Nature, 2011). In addition to these pathway mutations, we also identified a number of previously unreported gene mutations. Among these are a missense and a nonsense mutation involving two cohesin components, STAG1 and STAG2 found in single cases, respectively. Cohesin is a multimeric protein complex and enables post-replicative DNA repair and chromosome segregation by holding sister chromatids together during mitosis. To extend the findings in the whole-exome sequencing, we investigated mutations of cohesin complex, including STAG2/STAG1, SMC1A, SMC3 and RAD21, in 370 cases of myeloid malignancy by deep sequencing of pooled DNA. In total, 38 mutations were identified in 36 out of the 370 cases, where STAG2 and RAD21 accounted for most of the mutations. These mutations occurred in a completely mutually exclusive manner, suggesting a common impact of these mutations on the pathogenesis of myeloid neoplasms. Most mutations of STAG2 and RAD21 were nonsense or frameshift changes, or splice site mutations and widely distributed along the entire coding region, causing loss-of-function of the proteins. On the other hand, all mutations detected in SMC1A, SMC3, and STAG1 were missense changes, indicating that their functions are essential for tumor survival, complete loss of functions of which could lead to cell death. In cytogenetics, 11 cohesin-mutated cases had normal karyotypes, and only 16 out of the 36 tumors with cohesion mutations showed abnormal karyotypes, where most cases had near-diploid with only 2 patients having complex karyotypes. So far, several lines of evidence suggest that cohesin plays an important role for genomic stability and mutational inactivation of STAG2 was shown to cause aneuploidy in human cells. However, our results raise the possibility that alterations of cohesin genes could be involved in carcinogenesis at least partly through mechanisms other than causing aneuploidy. In this context, it is of note that growing evidence have shown that cohesin forms long-range chromosomal interactions and regulate gene expression in association with CTCF, mediator, or transcription factors. Further functional study should be warranted to gain new insights into the role of cohesin in the pathogenesis of myeloid malignancies as well as other human cancers. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 5117. doi:1538-7445.AM2012-5117
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2012
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 8
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 73, No. 8_Supplement ( 2013-04-15), p. 3802-3802
    Abstract: BACKGROUND Transient abnormal myelopoiesis (TAM) is known as a clonal myeloid proliferation affecting ∼10% of neonatal infants with Down syndrome (DS). Although spontaneous regression is as a rule in most cases, about 20-30% of the survived infants develop non-self-limited acute megakaryoblastic leukemia (AMKL) years after the remission. As for the molecular pathogenesis of TAM and DS-AMKL, it has been well established that GATA1 mutations are detected in virtually all TAM cases as well as DS-AMKL. However, it is still open to question whether a GATA1 mutation and trisomy 21 are sufficient for the development of TAM, what is the cellular origin of the subsequent AMKL and whether additional gene mutations are required for the progression to AMKL. METHODS To answer these questions, we performed a comprehensive analysis of somatic mutations in TAM/AMKL cases using whole genome sequencing of three trio samples sequentially obtained at the initial presentation of TAM, during remission and at the subsequent relapse phase of AMKL. Whole exome sequencing was also performed for TAM (N=15) and DS-AMKL (N=14) samples. The recurrent mutations in the discovery cohort were further screened in an extended cohort of TAM (N = 41) as well as DS-AMKL (N = 49) and other AMKL cases (N = 19). RESULTS TAM samples had significantly fewer numbers of somatic mutations compared to AMKL samples with the mean numbers of non-silent somatic mutations of 1.7 and 5.7 per sample in whole exome sequencing in TAM and AMKL cases, respectively (p=0.001). Whole genome sequencing and subsequent deep sequencing of the individual mutations revealed more complicated pictures of clonal evolutions leading to AMKL. Founding clones in TAM evolved into AMKL in two cases and, on the other hand, the direct ancestor of the AMKL clone in a remaining case could be back-traced to a more upstream branch-point of the evolution before the major TAM clone had appeared. While GATA1 was the only recurrent mutational target in the TAM phase, 8 genes were recurrently mutated in AMKL samples in whole exome sequencing, including NRAS, TP53 and other novel gene targets. The recurrent mutations found in the discovery cohort, in addition to known mutational targets in myeloid malignancies, were screened in an extended cohort of DS-associated myeloid disorders (N=90) as well as other AMKL cases, using high-throughput sequencing of hybrid-selection and/or PCR amplified targets. Secondary mutations other than GATA1 mutations were found in 6 out of 41 TAM, 38 out of 49 DS-AMKL and 10 out of 19 other AMKL cases. CONCLUSION TAM is characterized by a paucity of somatic mutations and thought to be virtually caused by a GATA1 mutation in combination with constitutive trisomy 21. We found two major clonal evolution patterns during DS-AMKL relapse. Secondary genetic hits other than GATA1 mutations were common in DS-AMKL and mutations involving genes such as tyrosine kinase and RAS pathway genes play a major role in clonal evolution into AMKL. Citation Format: Kenichi Yoshida, Tsutomu Toki, Myoung-ja Park, Yusuke Okuno, Yuichi Shiraishi, Masashi Sanada, Ayana Kon, Yasunobu Nagata, Aiko Sato-Otsubo, Yusuke Sato, RuNan Wang, Kiminori Terui, Rika Kanezaki, Norio Shiba, Kenichi Chiba, Hiroko Tanaka, Asahito Hama, Daisuke Hasegawa, Kazuhiro Nakamura, Hirokazu Kanegane, Keiko Tsukamoto, Souichi Adachi, Satoru Miyano, Seiji Kojima, Shai Izraeli, Yasuhide Hayashi, Etsuro Ito, Seishi Ogawa. Genetic basis of myeloid leukemogenesis in Down syndrome. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 3802. doi:10.1158/1538-7445.AM2013-3802
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2013
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 9
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 74, No. 19_Supplement ( 2014-10-01), p. 2229-2229
    Abstract: Low grade gliomas (LGGs) account for approximately half of all gliomas. Although LGGs typically show slower tumor progression and generally better clinical outcomes than high-grade gliomas, their clinical course is invariably indolent and most patients ultimately succumb to death. In contrast to high-grade tumors, our knowledge about the genetic lesions and clonal evolution in LGG is still incomplete. So, to obtain a complete registry of gene mutations involved in LGG pathogenesis and their role in clonal evolution, we performed whole exome sequencing (WES) of paired tumor/normal DNA from 54 cases with LGG. Clonal evolution in LGG was investigated using paired primary/relapsed tumor specimens from 9 cases as well as multiple tumor specimens (median 5) from 4cases. Major mutational targets detected in WES included not only previously known mutational genes, including IDH1/2, TP53, ATRX, CIC, FUBP1 and NOTCH1, as well as multiple components of the PI3K pathway and the SWI/SNF complex. Multi-sampling analysis revealed regional and special heterogeneity of LGG. According to the observed variant allele frequencies (VAFs), mutations of IDH1/2 and 1p19q co-deletion were thought to exist in the major clone, representing truncal mutations in most cases., In contrast, mutations in TP53, ATRX, CIC and FUBP1 were more often identified in one or more phylogenic branches in different subclones and involved in parallel evolution, where different mutations of the same genes were found at different time points in different locations. We further performed deep-sequencing of common mutational targets identified by WES and SNP array analysis among a large cohort of 327 LGG cases. As previously reported, mutations in IDH1/2 were found in 78.6%. 1p19q co-deletion (43.1%), and TP53 mutations (34.6%) with or without ATRX mutations were mutually exclusive with common IDH mutations. VAFs of coexisting IDH1/2 and 1p19q co-deletion were approximately the same, whereas mutations in other genes tended to show lower VAFs than those of IDH1/2. Combined, our findings revealed two major, mutually exclusive patterns in clonal evolution in LGG; in some cases IDH1/2 mutations and 1p19q co-deletions were trunchal events, followed by CIC, FUBP1, and other mutations in subsequent phylogenic branches. In other cases, predated by the founder IDH1/2 mutations, mutations in TP53 and ATRX seemed to predominate tumor populations after. Citation Format: Hiromichi Suzuki, Atsushi Natsume, Yusuke Sato, Yuichi Shiraishi, Yusuke Shiozawa, Kenichi Yoshida, Yasunobu Nagata, Aiko Sato, Kazuya Motomura, Masazumi Fujii, Masashi Sanada, Satoru Miyano, Toshihiko Wakabayashi, Seishi Ogawa. Whole exome sequencing reveals the landscape of gene mutations and evolution in low-grade glioma. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 2229. doi:10.1158/1538-7445.AM2014-2229
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2014
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 10
    In: Clinical Cancer Research, American Association for Cancer Research (AACR), Vol. 27, No. 4 ( 2021-02-15), p. 1150-1161
    Abstract: Hepatocellular carcinoma (HCC) is characterized by high intertumor heterogeneity of genetic drivers. Two multitarget tyrosine kinase inhibitors (TKI), lenvatinib and sorafenib, are used as standard-of-care chemotherapeutics in patients with advanced HCC, but a stratification strategy has not been established because of a lack of efficacious biomarkers. Therefore, we sought biomarkers that indicate lenvatinib-susceptible HCC. Experimental Design: We performed genetic screening of HCC driver genes involved in TKI susceptibility using a novel HCC mouse model in which tumor diversity of genetic drivers was recapitulated. A biomarker candidate was evaluated in human HCC cell lines. Secreted proteins from HCC cells were then screened using mass spectrometry. Serum and tumor levels of the biomarker candidates were analyzed for their association and prediction of overall survival in patients with HCC. Results: We found that lenvatinib selectively eliminated FGF19-expressing tumors, whereas sorafenib eliminated MET- and NRAS-expressing tumors. FGF19 levels and lenvatinib susceptibility were correlated in HCC cell lines, and FGF19 inhibition eliminated lenvatinib susceptibility. Lenvatinib-resistant HCC cell lines, generated by long-term exposure to lenvatinib, showed FGF19 downregulation but were resensitized to lenvatinib by FGF19 reexpression. Thus, FGF19 is a tumor biomarker of lenvatinib-susceptible HCC. Proteome and secretome analyses identified ST6GAL1 as a tumor-derived secreted protein positively regulated by FGF19 in HCC cells. Serum ST6GAL1 levels were positively correlated with tumor FGF19 expression in patients with surgically resected HCC. Among patients with serum ST6GAL1-high HCC who underwent TKI therapy, lenvatinib therapy showed significantly better survival than sorafenib. Conclusions: Serum ST6GAL may be a novel biomarker that identifies lenvatinib-susceptible FGF19-driven HCC.
    Type of Medium: Online Resource
    ISSN: 1078-0432 , 1557-3265
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2021
    detail.hit.zdb_id: 1225457-5
    detail.hit.zdb_id: 2036787-9
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...